ADAMA Ltd. (000553) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

000553 ADAMA Ltd.

Watchlist

6.00
-0.15-2.44%

Market Closed Jan 15 15:00 CST

13.98BMarket Cap-5.82P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Groundwork Bioag and Adama Announce Exclusive Commercial Agreement to Offer Rootella® Inoculants for Chinese Farmers
ReutersJan 6 05:34 ET
Health Check: How Prudently Does ADAMA (SZSE:000553) Use Debt?
Simply Wall StDec 25, 2024 19:46 ET
Express News | Adama Ltd: EU Commission Approval Anticipated in 2025; First Feralla-Based Product, Expected to Launch in UK That Same Year
ReutersDec 18, 2024 06:01 ET
Express News | Adama Ltd: Efsa Published Their Conclusion Regarding Novel, in-Licensed Active Ingredient Feralla in EU
ReutersDec 18, 2024 06:00 ET
Feralla, a New Active Ingredient for Mollusc Control by ADAMA, Nears EU Approval
PR NewswireDec 18, 2024 05:58 ET
ADAMA, Syngenta Sign Management Agreement for Overlapping Products
MT NewswiresNov 6, 2024 22:39 ET

Comments

Moomoo AI

Mar 22, 2024 20:34

The company's poor performance over the last year may indicate unresolved challenges, as it was worse than the annualised loss of 8% over the last half decade. However, the increase in revenue could suggest an opportunity for a turnaround.

Shareholders in ADAMA (SZSE:000553) Have Lost 47%, as Stock Drops 4.5% This Past Week

Moomoo AI

Jan 25, 2024 20:15

The declining ROCE trend and steady capital employed are not conducive to creating a multi-bagger, leading to a 32% stock fall over five years. Without a positive shift in these metrics, it may be wise to seek other investment opportunities.

Capital Allocation Trends At ADAMA (SZSE:000553) Aren't Ideal

Moomoo AI

Dec 27, 2023 23:45

ADAMA's lower P/S ratio indicates predicted limited growth due to revenue decline and lesser projected growth than the industry. A significant near-term stock price surge seems improbable.